Cardiovascular effects of growth hormone treatment in growth-hormone-deficient adults: stimulation of the renin-aldosterone system.

Cuneo RC, Salomon F, Wilmshurst P, Byrne C, Wiles CM, Hesp R, Sönksen PH

Clinical science (London, England : 1979)1 Nov 1991Cited by 82 (Europe PMC)

PMID1661645DOI10.1042/cs0810587PepBankPUB-01661645

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, rhGH increased left ventricular end-diastolic dimension compared with placebo.
In plain wordsIn GH-deficient adults, rhGH increased the heart's end-diastolic dimension compared with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseLeft ventricular end-diastolic dimension
Study
n = 24
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
0.07 units/kg at night · 6 monthsAs given in this study (human).
Source sentences
Summary
Compared with placebo, resting M-mode echocardiography showed increases in left ventricular end-diastolic dimension and stroke volume in the group treated with recombinant human growth hormone.
1 context sentence(design, population, supporting numbers)
Summary · context
The cardiovascular effects of growth hormone in adults with growth hormone deficiency were examined in 24 patients treated with recombinant human growth hormone (0.07 units/kg at night) in a double-blind, placebo-controlled trial lasting 6 months.
Report a problemFND-0166164501
02HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, rhGH increased stroke volume compared with placebo.
In plain wordsIn GH-deficient adults, rhGH increased stroke volume compared with placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseStroke volume
Study
n = 24
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
0.07 units/kg at night · 6 monthsAs given in this study (human).
Source sentences
Summary
Compared with placebo, resting M-mode echocardiography showed increases in left ventricular end-diastolic dimension and stroke volume in the group treated with recombinant human growth hormone.
1 context sentence(design, population, supporting numbers)
Summary · context
The cardiovascular effects of growth hormone in adults with growth hormone deficiency were examined in 24 patients treated with recombinant human growth hormone (0.07 units/kg at night) in a double-blind, placebo-controlled trial lasting 6 months.
Report a problemFND-0166164502
03HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, left ventricular end-systolic dimension did not differ between rhGH and placebo.
In plain wordsIn GH-deficient adults, the heart's end-systolic dimension did not differ between rhGH and placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeLeft ventricular end-systolic dimension
Study
n = 24
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
0.07 units/kg at night · 6 monthsAs given in this study (human).
Source sentences
Summary
No differences were noted between the groups with respect to left ventricular end-systolic dimension, fractional shortening, wall thicknesses or mean arterial blood pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
The cardiovascular effects of growth hormone in adults with growth hormone deficiency were examined in 24 patients treated with recombinant human growth hormone (0.07 units/kg at night) in a double-blind, placebo-controlled trial lasting 6 months.
Report a problemFND-0166164503
04HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, fractional shortening did not differ between rhGH and placebo.
In plain wordsIn GH-deficient adults, fractional shortening did not differ between rhGH and placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeFractional shortening
Study
n = 24
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
0.07 units/kg at night · 6 monthsAs given in this study (human).
Source sentences
Summary
No differences were noted between the groups with respect to left ventricular end-systolic dimension, fractional shortening, wall thicknesses or mean arterial blood pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
The cardiovascular effects of growth hormone in adults with growth hormone deficiency were examined in 24 patients treated with recombinant human growth hormone (0.07 units/kg at night) in a double-blind, placebo-controlled trial lasting 6 months.
Report a problemFND-0166164504
05HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, wall thicknesses did not differ between rhGH and placebo.
In plain wordsIn GH-deficient adults, heart wall thicknesses did not differ between rhGH and placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeWall thicknesses
Study
n = 24
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
0.07 units/kg at night · 6 monthsAs given in this study (human).
Source sentences
Summary
No differences were noted between the groups with respect to left ventricular end-systolic dimension, fractional shortening, wall thicknesses or mean arterial blood pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
The cardiovascular effects of growth hormone in adults with growth hormone deficiency were examined in 24 patients treated with recombinant human growth hormone (0.07 units/kg at night) in a double-blind, placebo-controlled trial lasting 6 months.
Report a problemFND-0166164505
06HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, mean arterial blood pressure did not differ between rhGH and placebo.
In plain wordsIn GH-deficient adults, mean blood pressure did not differ between rhGH and placebo.
Peptide
HGH (somatotropin)
Outcome
No significant changeMean arterial blood pressure
Study
n = 24
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.07 units/kg at night · 6 monthsAs given in this study (human).
Source sentences
Summary
No differences were noted between the groups with respect to left ventricular end-systolic dimension, fractional shortening, wall thicknesses or mean arterial blood pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
The cardiovascular effects of growth hormone in adults with growth hormone deficiency were examined in 24 patients treated with recombinant human growth hormone (0.07 units/kg at night) in a double-blind, placebo-controlled trial lasting 6 months.
Report a problemFND-0166164506
07HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, left ventricular myocardial mass increased with rhGH.
In plain wordsIn GH-deficient adults, heart muscle mass increased during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseLeft ventricular myocardial mass
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
0.07 units/kg at night · 6 monthsAs given in this study (human).
Source sentences
Summary
Left ventricular myocardial mass increased in the group given recombinant human growth hormone.
1 context sentence(design, population, supporting numbers)
Summary · context
The cardiovascular effects of growth hormone in adults with growth hormone deficiency were examined in 24 patients treated with recombinant human growth hormone (0.07 units/kg at night) in a double-blind, placebo-controlled trial lasting 6 months.
Report a problemFND-0166164507
08HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, supine plasma renin activity increased and remained elevated over 6 months of rhGH.
In plain wordsIn GH-deficient adults, renin activity increased and remained elevated during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseSupine plasma renin activity
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
0.07 units/kg at night · 6 monthsAs given in this study (human).
Source sentences
Summary
The supine plasma renin activity was increased and remained elevated over the 6 months, whereas the plasma aldosterone concentration was unchanged, after treatment with recombinant human growth hormone.
1 context sentence(design, population, supporting numbers)
Summary · context
The cardiovascular effects of growth hormone in adults with growth hormone deficiency were examined in 24 patients treated with recombinant human growth hormone (0.07 units/kg at night) in a double-blind, placebo-controlled trial lasting 6 months.
Report a problemFND-0166164508
09HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, plasma aldosterone remained unchanged after rhGH treatment.
In plain wordsIn GH-deficient adults, aldosterone did not change after rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changePlasma aldosterone
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
0.07 units/kg at night · 6 monthsAs given in this study (human).
Source sentences
Summary
The supine plasma renin activity was increased and remained elevated over the 6 months, whereas the plasma aldosterone concentration was unchanged, after treatment with recombinant human growth hormone.
1 context sentence(design, population, supporting numbers)
Summary · context
The cardiovascular effects of growth hormone in adults with growth hormone deficiency were examined in 24 patients treated with recombinant human growth hormone (0.07 units/kg at night) in a double-blind, placebo-controlled trial lasting 6 months.
Report a problemFND-0166164509
10HumanNon-randomized trialSafety outcome
In GH-deficient adults, clinical sodium retention appeared during the first 3 months of rhGH treatment.
In plain wordsIn GH-deficient adults, signs of sodium retention appeared during the first 3 months of rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
Not applicableSodium retention
Study
n: not reported in source
Outcome group
Adverse events · Cardiovascular
Studied dose
0.07 units/kg at night · 6 monthsAs given in this study (human).
Source sentences
Summary
Clinical signs of sodium retention were evident during the first 3 months of treatment with recombinant human growth hormone.
1 context sentence(design, population, supporting numbers)
Summary · context
The cardiovascular effects of growth hormone in adults with growth hormone deficiency were examined in 24 patients treated with recombinant human growth hormone (0.07 units/kg at night) in a double-blind, placebo-controlled trial lasting 6 months.
Report a problemFND-0166164510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.